nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclophosphamide—Mechlorethamine—hematologic cancer	0.316	0.54	CrCtD
Cyclophosphamide—Ifosfamide—hematologic cancer	0.269	0.46	CrCtD
Cyclophosphamide—ABCB1—hematologic cancer	0.0309	1	CbGaD
Cyclophosphamide—CYP2C18—Ifosfamide—hematologic cancer	0.0129	0.0515	CbGbCtD
Cyclophosphamide—CYP2A6—Methoxsalen—hematologic cancer	0.00858	0.0343	CbGbCtD
Cyclophosphamide—CYP2B6—Thiotepa—hematologic cancer	0.00718	0.0287	CbGbCtD
Cyclophosphamide—CYP2A6—Ifosfamide—hematologic cancer	0.00626	0.025	CbGbCtD
Cyclophosphamide—CYP2C9—Bexarotene—hematologic cancer	0.00458	0.0183	CbGbCtD
Cyclophosphamide—ABCB1—Lenalidomide—hematologic cancer	0.00444	0.0178	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Ifosfamide—hematologic cancer	0.00428	0.0171	CbGbCtD
Cyclophosphamide—CYP3A7—Ifosfamide—hematologic cancer	0.00428	0.0171	CbGbCtD
Cyclophosphamide—CYP2A6—Prednisolone—hematologic cancer	0.00417	0.0167	CbGbCtD
Cyclophosphamide—CYP3A7—Imatinib—hematologic cancer	0.00409	0.0164	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Imatinib—hematologic cancer	0.00409	0.0164	CbGbCtD
Cyclophosphamide—CYP2B6—Ifosfamide—hematologic cancer	0.00407	0.0163	CbGbCtD
Cyclophosphamide—CYP2C8—Bortezomib—hematologic cancer	0.00402	0.0161	CbGbCtD
Cyclophosphamide—CYP3A5—Daunorubicin—hematologic cancer	0.004	0.016	CbGbCtD
Cyclophosphamide—CYP2D6—Lomustine—hematologic cancer	0.00389	0.0156	CbGbCtD
Cyclophosphamide—CYP2C9—Idarubicin—hematologic cancer	0.00379	0.0152	CbGbCtD
Cyclophosphamide—CYP3A5—Thalidomide—hematologic cancer	0.00365	0.0146	CbGbCtD
Cyclophosphamide—CYP2B6—Nilotinib—hematologic cancer	0.00354	0.0142	CbGbCtD
Cyclophosphamide—CYP3A5—Teniposide—hematologic cancer	0.00348	0.0139	CbGbCtD
Cyclophosphamide—CYP2D6—Idarubicin—hematologic cancer	0.00347	0.0139	CbGbCtD
Cyclophosphamide—CYP2C19—Bortezomib—hematologic cancer	0.00338	0.0135	CbGbCtD
Cyclophosphamide—CYP3A5—Ifosfamide—hematologic cancer	0.00321	0.0128	CbGbCtD
Cyclophosphamide—CYP2C8—Ifosfamide—hematologic cancer	0.00309	0.0123	CbGbCtD
Cyclophosphamide—CYP3A5—Imatinib—hematologic cancer	0.00307	0.0123	CbGbCtD
Cyclophosphamide—CYP2D6—Hydroxyurea—hematologic cancer	0.00295	0.0118	CbGbCtD
Cyclophosphamide—CYP2C19—Thalidomide—hematologic cancer	0.00294	0.0118	CbGbCtD
Cyclophosphamide—CYP2C9—Bortezomib—hematologic cancer	0.00281	0.0112	CbGbCtD
Cyclophosphamide—CYP2C19—Teniposide—hematologic cancer	0.00281	0.0112	CbGbCtD
Cyclophosphamide—CYP2C8—Nilotinib—hematologic cancer	0.00268	0.0107	CbGbCtD
Cyclophosphamide—CYP3A4—Bexarotene—hematologic cancer	0.00266	0.0107	CbGbCtD
Cyclophosphamide—ABCB1—Daunorubicin—hematologic cancer	0.0026	0.0104	CbGbCtD
Cyclophosphamide—CYP2C19—Ifosfamide—hematologic cancer	0.00259	0.0104	CbGbCtD
Cyclophosphamide—CYP2D6—Bortezomib—hematologic cancer	0.00257	0.0103	CbGbCtD
Cyclophosphamide—CYP3A7—Irinotecan—hematologic cancer	0.00255	0.0102	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Irinotecan—hematologic cancer	0.00255	0.0102	CbGbCtD
Cyclophosphamide—ABCB1—Alitretinoin—hematologic cancer	0.00255	0.0102	CbGbCtD
Cyclophosphamide—CYP3A4—Lomustine—hematologic cancer	0.00247	0.0099	CbGbCtD
Cyclophosphamide—CYP3A4—Busulfan—hematologic cancer	0.00247	0.0099	CbGbCtD
Cyclophosphamide—CYP2C19—Imatinib—hematologic cancer	0.00247	0.0099	CbGbCtD
Cyclophosphamide—CYP3A5—Dasatinib—hematologic cancer	0.00246	0.00985	CbGbCtD
Cyclophosphamide—CYP2A6—Dexamethasone—hematologic cancer	0.00246	0.00984	CbGbCtD
Cyclophosphamide—CYP2C9—Thalidomide—hematologic cancer	0.00244	0.00978	CbGbCtD
Cyclophosphamide—CYP2B6—Irinotecan—hematologic cancer	0.00243	0.00973	CbGbCtD
Cyclophosphamide—CYP2C9—Teniposide—hematologic cancer	0.00233	0.00933	CbGbCtD
Cyclophosphamide—CYP3A7—Vincristine—hematologic cancer	0.00223	0.00893	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Vincristine—hematologic cancer	0.00223	0.00893	CbGbCtD
Cyclophosphamide—CYP3A4—Thiotepa—hematologic cancer	0.00221	0.00883	CbGbCtD
Cyclophosphamide—CYP2C9—Ifosfamide—hematologic cancer	0.00215	0.00861	CbGbCtD
Cyclophosphamide—CYP2C9—Imatinib—hematologic cancer	0.00206	0.00823	CbGbCtD
Cyclophosphamide—ABCB1—Imatinib—hematologic cancer	0.002	0.00799	CbGbCtD
Cyclophosphamide—CYP2B6—Cisplatin—hematologic cancer	0.00198	0.00793	CbGbCtD
Cyclophosphamide—CYP3A5—Irinotecan—hematologic cancer	0.00191	0.00766	CbGbCtD
Cyclophosphamide—CYP2D6—Imatinib—hematologic cancer	0.00188	0.00752	CbGbCtD
Cyclophosphamide—CYP2C9—Nilotinib—hematologic cancer	0.00187	0.00748	CbGbCtD
Cyclophosphamide—ABCB1—Nilotinib—hematologic cancer	0.00181	0.00726	CbGbCtD
Cyclophosphamide—ABCB1—Vinorelbine—hematologic cancer	0.0018	0.0072	CbGbCtD
Cyclophosphamide—CYP3A4—Methoxsalen—hematologic cancer	0.00172	0.00687	CbGbCtD
Cyclophosphamide—CYP2D6—Nilotinib—hematologic cancer	0.00171	0.00684	CbGbCtD
Cyclophosphamide—CYP2D6—Vinorelbine—hematologic cancer	0.00169	0.00678	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Dexamethasone—hematologic cancer	0.00168	0.00673	CbGbCtD
Cyclophosphamide—CYP3A7—Dexamethasone—hematologic cancer	0.00168	0.00673	CbGbCtD
Cyclophosphamide—CYP3A5—Vincristine—hematologic cancer	0.00167	0.0067	CbGbCtD
Cyclophosphamide—CYP3A4—Bortezomib—hematologic cancer	0.00163	0.00653	CbGbCtD
Cyclophosphamide—CYP2C19—Prednisone—hematologic cancer	0.00163	0.00652	CbGbCtD
Cyclophosphamide—ABCB1—Dasatinib—hematologic cancer	0.0016	0.00641	CbGbCtD
Cyclophosphamide—CYP2B6—Dexamethasone—hematologic cancer	0.0016	0.00641	CbGbCtD
Cyclophosphamide—ABCB1—Mitoxantrone—hematologic cancer	0.00158	0.00634	CbGbCtD
Cyclophosphamide—CYP3A4—Daunorubicin—hematologic cancer	0.00156	0.00625	CbGbCtD
Cyclophosphamide—CYP3A5—Etoposide—hematologic cancer	0.00153	0.00614	CbGbCtD
Cyclophosphamide—CYP2C8—Etoposide—hematologic cancer	0.00147	0.0059	CbGbCtD
Cyclophosphamide—ABCB1—Betamethasone—hematologic cancer	0.00141	0.00565	CbGbCtD
Cyclophosphamide—ABCB1—Gemcitabine—hematologic cancer	0.0014	0.0056	CbGbCtD
Cyclophosphamide—ABCB1—Prednisolone—hematologic cancer	0.00139	0.00557	CbGbCtD
Cyclophosphamide—CYP3A4—Cytarabine—hematologic cancer	0.00138	0.00551	CbGbCtD
Cyclophosphamide—CYP3A4—Teniposide—hematologic cancer	0.00136	0.00543	CbGbCtD
Cyclophosphamide—CYP2B6—Doxorubicin—hematologic cancer	0.00133	0.00531	CbGbCtD
Cyclophosphamide—ABCB1—Prednisone—hematologic cancer	0.00131	0.00526	CbGbCtD
Cyclophosphamide—CYP3A5—Dexamethasone—hematologic cancer	0.00126	0.00505	CbGbCtD
Cyclophosphamide—CYP3A4—Ifosfamide—hematologic cancer	0.00125	0.00501	CbGbCtD
Cyclophosphamide—ABCB1—Irinotecan—hematologic cancer	0.00125	0.00499	CbGbCtD
Cyclophosphamide—CYP2C8—Dexamethasone—hematologic cancer	0.00121	0.00485	CbGbCtD
Cyclophosphamide—CYP3A4—Imatinib—hematologic cancer	0.0012	0.00478	CbGbCtD
Cyclophosphamide—CYP3A4—Ruxolitinib—hematologic cancer	0.00113	0.00451	CbGbCtD
Cyclophosphamide—ABCB1—Vinblastine—hematologic cancer	0.00111	0.00443	CbGbCtD
Cyclophosphamide—ABCB1—Vincristine—hematologic cancer	0.00109	0.00436	CbGbCtD
Cyclophosphamide—CYP3A4—Nilotinib—hematologic cancer	0.00109	0.00435	CbGbCtD
Cyclophosphamide—CYP3A4—Vinorelbine—hematologic cancer	0.00108	0.00431	CbGbCtD
Cyclophosphamide—CYP2C9—Cisplatin—hematologic cancer	0.00105	0.00419	CbGbCtD
Cyclophosphamide—CYP2D6—Vinblastine—hematologic cancer	0.00104	0.00418	CbGbCtD
Cyclophosphamide—CYP2C19—Dexamethasone—hematologic cancer	0.00102	0.00407	CbGbCtD
Cyclophosphamide—ABCB1—Cisplatin—hematologic cancer	0.00102	0.00407	CbGbCtD
Cyclophosphamide—ABCB1—Etoposide—hematologic cancer	0.000998	0.00399	CbGbCtD
Cyclophosphamide—CYP3A4—Triamcinolone—hematologic cancer	0.000985	0.00394	CbGbCtD
Cyclophosphamide—CYP3A4—Dasatinib—hematologic cancer	0.00096	0.00384	CbGbCtD
Cyclophosphamide—CYP3A4—Mitoxantrone—hematologic cancer	0.000948	0.0038	CbGbCtD
Cyclophosphamide—CYP2C9—Dexamethasone—hematologic cancer	0.000846	0.00338	CbGbCtD
Cyclophosphamide—CYP3A4—Betamethasone—hematologic cancer	0.000845	0.00338	CbGbCtD
Cyclophosphamide—CYP3A4—Prednisolone—hematologic cancer	0.000834	0.00334	CbGbCtD
Cyclophosphamide—ABCB1—Dexamethasone—hematologic cancer	0.000821	0.00328	CbGbCtD
Cyclophosphamide—CYP3A4—Prednisone—hematologic cancer	0.000788	0.00315	CbGbCtD
Cyclophosphamide—CYP2D6—Dexamethasone—hematologic cancer	0.000773	0.00309	CbGbCtD
Cyclophosphamide—CYP3A4—Irinotecan—hematologic cancer	0.000747	0.00299	CbGbCtD
Cyclophosphamide—ABCB1—Doxorubicin—hematologic cancer	0.000681	0.00272	CbGbCtD
Cyclophosphamide—CYP3A4—Vinblastine—hematologic cancer	0.000664	0.00266	CbGbCtD
Cyclophosphamide—ABCB1—Methotrexate—hematologic cancer	0.00066	0.00264	CbGbCtD
Cyclophosphamide—CYP3A4—Vincristine—hematologic cancer	0.000653	0.00261	CbGbCtD
Cyclophosphamide—CYP2D6—Doxorubicin—hematologic cancer	0.000642	0.00257	CbGbCtD
Cyclophosphamide—CYP3A4—Etoposide—hematologic cancer	0.000598	0.00239	CbGbCtD
Cyclophosphamide—CYP3A4—Dexamethasone—hematologic cancer	0.000492	0.00197	CbGbCtD
Cyclophosphamide—CYP3A4—Doxorubicin—hematologic cancer	0.000408	0.00163	CbGbCtD
Cyclophosphamide—Erythema multiforme—Epirubicin—hematologic cancer	4.45e-06	3.66e-05	CcSEcCtD
Cyclophosphamide—Alopecia—Methotrexate—hematologic cancer	4.44e-06	3.65e-05	CcSEcCtD
Cyclophosphamide—Vomiting—Gemcitabine—hematologic cancer	4.44e-06	3.65e-05	CcSEcCtD
Cyclophosphamide—Bradycardia—Doxorubicin—hematologic cancer	4.43e-06	3.64e-05	CcSEcCtD
Cyclophosphamide—Paraesthesia—Dexamethasone—hematologic cancer	4.4e-06	3.62e-05	CcSEcCtD
Cyclophosphamide—Paraesthesia—Betamethasone—hematologic cancer	4.4e-06	3.62e-05	CcSEcCtD
Cyclophosphamide—Discomfort—Prednisone—hematologic cancer	4.4e-06	3.62e-05	CcSEcCtD
Cyclophosphamide—Rash—Gemcitabine—hematologic cancer	4.4e-06	3.62e-05	CcSEcCtD
Cyclophosphamide—Dermatitis—Gemcitabine—hematologic cancer	4.4e-06	3.62e-05	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Etoposide—hematologic cancer	4.39e-06	3.61e-05	CcSEcCtD
Cyclophosphamide—Tinnitus—Epirubicin—hematologic cancer	4.38e-06	3.61e-05	CcSEcCtD
Cyclophosphamide—Erythema—Methotrexate—hematologic cancer	4.37e-06	3.6e-05	CcSEcCtD
Cyclophosphamide—Haemoglobin—Doxorubicin—hematologic cancer	4.37e-06	3.6e-05	CcSEcCtD
Cyclophosphamide—Headache—Gemcitabine—hematologic cancer	4.37e-06	3.6e-05	CcSEcCtD
Cyclophosphamide—Nausea—Vincristine—hematologic cancer	4.37e-06	3.59e-05	CcSEcCtD
Cyclophosphamide—Flushing—Epirubicin—hematologic cancer	4.36e-06	3.59e-05	CcSEcCtD
Cyclophosphamide—Rhinitis—Doxorubicin—hematologic cancer	4.36e-06	3.59e-05	CcSEcCtD
Cyclophosphamide—Hepatitis—Doxorubicin—hematologic cancer	4.35e-06	3.58e-05	CcSEcCtD
Cyclophosphamide—Haemorrhage—Doxorubicin—hematologic cancer	4.35e-06	3.58e-05	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Prednisolone—hematologic cancer	4.33e-06	3.56e-05	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Doxorubicin—hematologic cancer	4.33e-06	3.56e-05	CcSEcCtD
Cyclophosphamide—Urticaria—Triamcinolone—hematologic cancer	4.29e-06	3.53e-05	CcSEcCtD
Cyclophosphamide—Dysgeusia—Methotrexate—hematologic cancer	4.28e-06	3.52e-05	CcSEcCtD
Cyclophosphamide—Asthenia—Etoposide—hematologic cancer	4.28e-06	3.52e-05	CcSEcCtD
Cyclophosphamide—Body temperature increased—Triamcinolone—hematologic cancer	4.27e-06	3.52e-05	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Prednisone—hematologic cancer	4.27e-06	3.51e-05	CcSEcCtD
Cyclophosphamide—Oedema—Prednisone—hematologic cancer	4.27e-06	3.51e-05	CcSEcCtD
Cyclophosphamide—Decreased appetite—Betamethasone—hematologic cancer	4.26e-06	3.51e-05	CcSEcCtD
Cyclophosphamide—Decreased appetite—Dexamethasone—hematologic cancer	4.26e-06	3.51e-05	CcSEcCtD
Cyclophosphamide—Nausea—Mitoxantrone—hematologic cancer	4.26e-06	3.5e-05	CcSEcCtD
Cyclophosphamide—Nausea—Irinotecan—hematologic cancer	4.26e-06	3.5e-05	CcSEcCtD
Cyclophosphamide—Infection—Prednisone—hematologic cancer	4.24e-06	3.49e-05	CcSEcCtD
Cyclophosphamide—Fatigue—Dexamethasone—hematologic cancer	4.23e-06	3.48e-05	CcSEcCtD
Cyclophosphamide—Fatigue—Betamethasone—hematologic cancer	4.23e-06	3.48e-05	CcSEcCtD
Cyclophosphamide—Chills—Epirubicin—hematologic cancer	4.22e-06	3.47e-05	CcSEcCtD
Cyclophosphamide—Pruritus—Etoposide—hematologic cancer	4.22e-06	3.47e-05	CcSEcCtD
Cyclophosphamide—Shock—Prednisone—hematologic cancer	4.2e-06	3.46e-05	CcSEcCtD
Cyclophosphamide—Arrhythmia—Epirubicin—hematologic cancer	4.2e-06	3.46e-05	CcSEcCtD
Cyclophosphamide—Pain—Betamethasone—hematologic cancer	4.19e-06	3.45e-05	CcSEcCtD
Cyclophosphamide—Pain—Dexamethasone—hematologic cancer	4.19e-06	3.45e-05	CcSEcCtD
Cyclophosphamide—Visual impairment—Doxorubicin—hematologic cancer	4.19e-06	3.45e-05	CcSEcCtD
Cyclophosphamide—Tachycardia—Prednisone—hematologic cancer	4.17e-06	3.43e-05	CcSEcCtD
Cyclophosphamide—Alopecia—Epirubicin—hematologic cancer	4.15e-06	3.42e-05	CcSEcCtD
Cyclophosphamide—Nausea—Gemcitabine—hematologic cancer	4.15e-06	3.41e-05	CcSEcCtD
Cyclophosphamide—Vomiting—Cisplatin—hematologic cancer	4.14e-06	3.4e-05	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Prednisone—hematologic cancer	4.13e-06	3.4e-05	CcSEcCtD
Cyclophosphamide—Vision blurred—Methotrexate—hematologic cancer	4.12e-06	3.39e-05	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Doxorubicin—hematologic cancer	4.11e-06	3.38e-05	CcSEcCtD
Cyclophosphamide—Rash—Cisplatin—hematologic cancer	4.1e-06	3.37e-05	CcSEcCtD
Cyclophosphamide—Dermatitis—Cisplatin—hematologic cancer	4.1e-06	3.37e-05	CcSEcCtD
Cyclophosphamide—Erythema—Epirubicin—hematologic cancer	4.09e-06	3.37e-05	CcSEcCtD
Cyclophosphamide—Diarrhoea—Etoposide—hematologic cancer	4.08e-06	3.35e-05	CcSEcCtD
Cyclophosphamide—Anorexia—Prednisone—hematologic cancer	4.07e-06	3.35e-05	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Methotrexate—hematologic cancer	4.06e-06	3.34e-05	CcSEcCtD
Cyclophosphamide—Tinnitus—Doxorubicin—hematologic cancer	4.06e-06	3.34e-05	CcSEcCtD
Cyclophosphamide—Anaemia—Methotrexate—hematologic cancer	4.04e-06	3.33e-05	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Dexamethasone—hematologic cancer	4.04e-06	3.32e-05	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Betamethasone—hematologic cancer	4.04e-06	3.32e-05	CcSEcCtD
Cyclophosphamide—Flushing—Doxorubicin—hematologic cancer	4.04e-06	3.32e-05	CcSEcCtD
Cyclophosphamide—Dysgeusia—Epirubicin—hematologic cancer	4.01e-06	3.3e-05	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Triamcinolone—hematologic cancer	3.98e-06	3.28e-05	CcSEcCtD
Cyclophosphamide—Malaise—Methotrexate—hematologic cancer	3.94e-06	3.24e-05	CcSEcCtD
Cyclophosphamide—Dizziness—Etoposide—hematologic cancer	3.94e-06	3.24e-05	CcSEcCtD
Cyclophosphamide—Muscle spasms—Epirubicin—hematologic cancer	3.94e-06	3.24e-05	CcSEcCtD
Cyclophosphamide—Leukopenia—Methotrexate—hematologic cancer	3.91e-06	3.22e-05	CcSEcCtD
Cyclophosphamide—Chills—Doxorubicin—hematologic cancer	3.9e-06	3.21e-05	CcSEcCtD
Cyclophosphamide—Urticaria—Dexamethasone—hematologic cancer	3.9e-06	3.21e-05	CcSEcCtD
Cyclophosphamide—Urticaria—Betamethasone—hematologic cancer	3.9e-06	3.21e-05	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Prednisone—hematologic cancer	3.89e-06	3.2e-05	CcSEcCtD
Cyclophosphamide—Dizziness—Prednisolone—hematologic cancer	3.89e-06	3.2e-05	CcSEcCtD
Cyclophosphamide—Arrhythmia—Doxorubicin—hematologic cancer	3.89e-06	3.2e-05	CcSEcCtD
Cyclophosphamide—Asthenia—Triamcinolone—hematologic cancer	3.88e-06	3.19e-05	CcSEcCtD
Cyclophosphamide—Body temperature increased—Betamethasone—hematologic cancer	3.88e-06	3.19e-05	CcSEcCtD
Cyclophosphamide—Body temperature increased—Dexamethasone—hematologic cancer	3.88e-06	3.19e-05	CcSEcCtD
Cyclophosphamide—Nausea—Cisplatin—hematologic cancer	3.86e-06	3.18e-05	CcSEcCtD
Cyclophosphamide—Vision blurred—Epirubicin—hematologic cancer	3.86e-06	3.17e-05	CcSEcCtD
Cyclophosphamide—Alopecia—Doxorubicin—hematologic cancer	3.84e-06	3.16e-05	CcSEcCtD
Cyclophosphamide—Paraesthesia—Prednisone—hematologic cancer	3.84e-06	3.15e-05	CcSEcCtD
Cyclophosphamide—Pruritus—Triamcinolone—hematologic cancer	3.82e-06	3.15e-05	CcSEcCtD
Cyclophosphamide—Cough—Methotrexate—hematologic cancer	3.82e-06	3.14e-05	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Epirubicin—hematologic cancer	3.8e-06	3.12e-05	CcSEcCtD
Cyclophosphamide—Convulsion—Methotrexate—hematologic cancer	3.79e-06	3.12e-05	CcSEcCtD
Cyclophosphamide—Vomiting—Etoposide—hematologic cancer	3.79e-06	3.12e-05	CcSEcCtD
Cyclophosphamide—Erythema—Doxorubicin—hematologic cancer	3.79e-06	3.12e-05	CcSEcCtD
Cyclophosphamide—Anaemia—Epirubicin—hematologic cancer	3.78e-06	3.11e-05	CcSEcCtD
Cyclophosphamide—Agitation—Epirubicin—hematologic cancer	3.76e-06	3.09e-05	CcSEcCtD
Cyclophosphamide—Rash—Etoposide—hematologic cancer	3.76e-06	3.09e-05	CcSEcCtD
Cyclophosphamide—Dermatitis—Etoposide—hematologic cancer	3.75e-06	3.09e-05	CcSEcCtD
Cyclophosphamide—Headache—Etoposide—hematologic cancer	3.73e-06	3.07e-05	CcSEcCtD
Cyclophosphamide—Arthralgia—Methotrexate—hematologic cancer	3.72e-06	3.06e-05	CcSEcCtD
Cyclophosphamide—Chest pain—Methotrexate—hematologic cancer	3.72e-06	3.06e-05	CcSEcCtD
Cyclophosphamide—Myalgia—Methotrexate—hematologic cancer	3.72e-06	3.06e-05	CcSEcCtD
Cyclophosphamide—Decreased appetite—Prednisone—hematologic cancer	3.71e-06	3.05e-05	CcSEcCtD
Cyclophosphamide—Dysgeusia—Doxorubicin—hematologic cancer	3.71e-06	3.05e-05	CcSEcCtD
Cyclophosphamide—Rash—Prednisolone—hematologic cancer	3.71e-06	3.05e-05	CcSEcCtD
Cyclophosphamide—Dermatitis—Prednisolone—hematologic cancer	3.7e-06	3.05e-05	CcSEcCtD
Cyclophosphamide—Malaise—Epirubicin—hematologic cancer	3.69e-06	3.04e-05	CcSEcCtD
Cyclophosphamide—Fatigue—Prednisone—hematologic cancer	3.68e-06	3.03e-05	CcSEcCtD
Cyclophosphamide—Headache—Prednisolone—hematologic cancer	3.68e-06	3.03e-05	CcSEcCtD
Cyclophosphamide—Discomfort—Methotrexate—hematologic cancer	3.68e-06	3.03e-05	CcSEcCtD
Cyclophosphamide—Leukopenia—Epirubicin—hematologic cancer	3.66e-06	3.01e-05	CcSEcCtD
Cyclophosphamide—Constipation—Prednisone—hematologic cancer	3.65e-06	3e-05	CcSEcCtD
Cyclophosphamide—Muscle spasms—Doxorubicin—hematologic cancer	3.64e-06	3e-05	CcSEcCtD
Cyclophosphamide—Palpitations—Epirubicin—hematologic cancer	3.62e-06	2.98e-05	CcSEcCtD
Cyclophosphamide—Confusional state—Methotrexate—hematologic cancer	3.6e-06	2.96e-05	CcSEcCtD
Cyclophosphamide—Dizziness—Triamcinolone—hematologic cancer	3.57e-06	2.94e-05	CcSEcCtD
Cyclophosphamide—Cough—Epirubicin—hematologic cancer	3.57e-06	2.94e-05	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Methotrexate—hematologic cancer	3.57e-06	2.94e-05	CcSEcCtD
Cyclophosphamide—Vision blurred—Doxorubicin—hematologic cancer	3.57e-06	2.94e-05	CcSEcCtD
Cyclophosphamide—Convulsion—Epirubicin—hematologic cancer	3.55e-06	2.92e-05	CcSEcCtD
Cyclophosphamide—Infection—Methotrexate—hematologic cancer	3.55e-06	2.92e-05	CcSEcCtD
Cyclophosphamide—Nausea—Etoposide—hematologic cancer	3.54e-06	2.91e-05	CcSEcCtD
Cyclophosphamide—Hypertension—Epirubicin—hematologic cancer	3.53e-06	2.91e-05	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Prednisone—hematologic cancer	3.52e-06	2.9e-05	CcSEcCtD
Cyclophosphamide—Asthenia—Dexamethasone—hematologic cancer	3.52e-06	2.89e-05	CcSEcCtD
Cyclophosphamide—Asthenia—Betamethasone—hematologic cancer	3.52e-06	2.89e-05	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Doxorubicin—hematologic cancer	3.51e-06	2.89e-05	CcSEcCtD
Cyclophosphamide—Anaemia—Doxorubicin—hematologic cancer	3.5e-06	2.88e-05	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Methotrexate—hematologic cancer	3.49e-06	2.88e-05	CcSEcCtD
Cyclophosphamide—Nausea—Prednisolone—hematologic cancer	3.49e-06	2.87e-05	CcSEcCtD
Cyclophosphamide—Chest pain—Epirubicin—hematologic cancer	3.48e-06	2.87e-05	CcSEcCtD
Cyclophosphamide—Myalgia—Epirubicin—hematologic cancer	3.48e-06	2.87e-05	CcSEcCtD
Cyclophosphamide—Arthralgia—Epirubicin—hematologic cancer	3.48e-06	2.87e-05	CcSEcCtD
Cyclophosphamide—Agitation—Doxorubicin—hematologic cancer	3.48e-06	2.86e-05	CcSEcCtD
Cyclophosphamide—Pruritus—Betamethasone—hematologic cancer	3.47e-06	2.85e-05	CcSEcCtD
Cyclophosphamide—Pruritus—Dexamethasone—hematologic cancer	3.47e-06	2.85e-05	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Methotrexate—hematologic cancer	3.45e-06	2.84e-05	CcSEcCtD
Cyclophosphamide—Discomfort—Epirubicin—hematologic cancer	3.44e-06	2.83e-05	CcSEcCtD
Cyclophosphamide—Vomiting—Triamcinolone—hematologic cancer	3.44e-06	2.83e-05	CcSEcCtD
Cyclophosphamide—Malaise—Doxorubicin—hematologic cancer	3.42e-06	2.81e-05	CcSEcCtD
Cyclophosphamide—Rash—Triamcinolone—hematologic cancer	3.41e-06	2.8e-05	CcSEcCtD
Cyclophosphamide—Dermatitis—Triamcinolone—hematologic cancer	3.4e-06	2.8e-05	CcSEcCtD
Cyclophosphamide—Anorexia—Methotrexate—hematologic cancer	3.4e-06	2.8e-05	CcSEcCtD
Cyclophosphamide—Urticaria—Prednisone—hematologic cancer	3.39e-06	2.79e-05	CcSEcCtD
Cyclophosphamide—Leukopenia—Doxorubicin—hematologic cancer	3.39e-06	2.79e-05	CcSEcCtD
Cyclophosphamide—Headache—Triamcinolone—hematologic cancer	3.39e-06	2.79e-05	CcSEcCtD
Cyclophosphamide—Body temperature increased—Prednisone—hematologic cancer	3.38e-06	2.78e-05	CcSEcCtD
Cyclophosphamide—Confusional state—Epirubicin—hematologic cancer	3.37e-06	2.77e-05	CcSEcCtD
Cyclophosphamide—Diarrhoea—Dexamethasone—hematologic cancer	3.36e-06	2.76e-05	CcSEcCtD
Cyclophosphamide—Diarrhoea—Betamethasone—hematologic cancer	3.36e-06	2.76e-05	CcSEcCtD
Cyclophosphamide—Palpitations—Doxorubicin—hematologic cancer	3.35e-06	2.75e-05	CcSEcCtD
Cyclophosphamide—Oedema—Epirubicin—hematologic cancer	3.34e-06	2.75e-05	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Epirubicin—hematologic cancer	3.34e-06	2.75e-05	CcSEcCtD
Cyclophosphamide—Hypotension—Methotrexate—hematologic cancer	3.34e-06	2.74e-05	CcSEcCtD
Cyclophosphamide—Infection—Epirubicin—hematologic cancer	3.32e-06	2.73e-05	CcSEcCtD
Cyclophosphamide—Cough—Doxorubicin—hematologic cancer	3.3e-06	2.72e-05	CcSEcCtD
Cyclophosphamide—Shock—Epirubicin—hematologic cancer	3.29e-06	2.7e-05	CcSEcCtD
Cyclophosphamide—Convulsion—Doxorubicin—hematologic cancer	3.28e-06	2.7e-05	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Epirubicin—hematologic cancer	3.27e-06	2.69e-05	CcSEcCtD
Cyclophosphamide—Hypertension—Doxorubicin—hematologic cancer	3.27e-06	2.69e-05	CcSEcCtD
Cyclophosphamide—Tachycardia—Epirubicin—hematologic cancer	3.26e-06	2.68e-05	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Methotrexate—hematologic cancer	3.25e-06	2.68e-05	CcSEcCtD
Cyclophosphamide—Dizziness—Dexamethasone—hematologic cancer	3.24e-06	2.67e-05	CcSEcCtD
Cyclophosphamide—Dizziness—Betamethasone—hematologic cancer	3.24e-06	2.67e-05	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Epirubicin—hematologic cancer	3.23e-06	2.66e-05	CcSEcCtD
Cyclophosphamide—Arthralgia—Doxorubicin—hematologic cancer	3.22e-06	2.65e-05	CcSEcCtD
Cyclophosphamide—Chest pain—Doxorubicin—hematologic cancer	3.22e-06	2.65e-05	CcSEcCtD
Cyclophosphamide—Myalgia—Doxorubicin—hematologic cancer	3.22e-06	2.65e-05	CcSEcCtD
Cyclophosphamide—Nausea—Triamcinolone—hematologic cancer	3.21e-06	2.64e-05	CcSEcCtD
Cyclophosphamide—Paraesthesia—Methotrexate—hematologic cancer	3.21e-06	2.64e-05	CcSEcCtD
Cyclophosphamide—Discomfort—Doxorubicin—hematologic cancer	3.19e-06	2.62e-05	CcSEcCtD
Cyclophosphamide—Anorexia—Epirubicin—hematologic cancer	3.18e-06	2.62e-05	CcSEcCtD
Cyclophosphamide—Dyspnoea—Methotrexate—hematologic cancer	3.18e-06	2.62e-05	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Prednisone—hematologic cancer	3.15e-06	2.59e-05	CcSEcCtD
Cyclophosphamide—Hypotension—Epirubicin—hematologic cancer	3.12e-06	2.57e-05	CcSEcCtD
Cyclophosphamide—Vomiting—Betamethasone—hematologic cancer	3.12e-06	2.57e-05	CcSEcCtD
Cyclophosphamide—Vomiting—Dexamethasone—hematologic cancer	3.12e-06	2.57e-05	CcSEcCtD
Cyclophosphamide—Confusional state—Doxorubicin—hematologic cancer	3.12e-06	2.56e-05	CcSEcCtD
Cyclophosphamide—Decreased appetite—Methotrexate—hematologic cancer	3.1e-06	2.55e-05	CcSEcCtD
Cyclophosphamide—Rash—Betamethasone—hematologic cancer	3.09e-06	2.54e-05	CcSEcCtD
Cyclophosphamide—Rash—Dexamethasone—hematologic cancer	3.09e-06	2.54e-05	CcSEcCtD
Cyclophosphamide—Oedema—Doxorubicin—hematologic cancer	3.09e-06	2.54e-05	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Doxorubicin—hematologic cancer	3.09e-06	2.54e-05	CcSEcCtD
Cyclophosphamide—Dermatitis—Dexamethasone—hematologic cancer	3.09e-06	2.54e-05	CcSEcCtD
Cyclophosphamide—Dermatitis—Betamethasone—hematologic cancer	3.09e-06	2.54e-05	CcSEcCtD
Cyclophosphamide—Fatigue—Methotrexate—hematologic cancer	3.08e-06	2.53e-05	CcSEcCtD
Cyclophosphamide—Headache—Betamethasone—hematologic cancer	3.07e-06	2.53e-05	CcSEcCtD
Cyclophosphamide—Headache—Dexamethasone—hematologic cancer	3.07e-06	2.53e-05	CcSEcCtD
Cyclophosphamide—Infection—Doxorubicin—hematologic cancer	3.07e-06	2.53e-05	CcSEcCtD
Cyclophosphamide—Asthenia—Prednisone—hematologic cancer	3.06e-06	2.52e-05	CcSEcCtD
Cyclophosphamide—Pain—Methotrexate—hematologic cancer	3.05e-06	2.51e-05	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Epirubicin—hematologic cancer	3.04e-06	2.5e-05	CcSEcCtD
Cyclophosphamide—Shock—Doxorubicin—hematologic cancer	3.04e-06	2.5e-05	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Doxorubicin—hematologic cancer	3.03e-06	2.49e-05	CcSEcCtD
Cyclophosphamide—Pruritus—Prednisone—hematologic cancer	3.02e-06	2.49e-05	CcSEcCtD
Cyclophosphamide—Tachycardia—Doxorubicin—hematologic cancer	3.02e-06	2.48e-05	CcSEcCtD
Cyclophosphamide—Paraesthesia—Epirubicin—hematologic cancer	3e-06	2.47e-05	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Doxorubicin—hematologic cancer	2.99e-06	2.46e-05	CcSEcCtD
Cyclophosphamide—Dyspnoea—Epirubicin—hematologic cancer	2.98e-06	2.45e-05	CcSEcCtD
Cyclophosphamide—Anorexia—Doxorubicin—hematologic cancer	2.95e-06	2.42e-05	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Methotrexate—hematologic cancer	2.94e-06	2.42e-05	CcSEcCtD
Cyclophosphamide—Diarrhoea—Prednisone—hematologic cancer	2.92e-06	2.4e-05	CcSEcCtD
Cyclophosphamide—Nausea—Dexamethasone—hematologic cancer	2.91e-06	2.4e-05	CcSEcCtD
Cyclophosphamide—Nausea—Betamethasone—hematologic cancer	2.91e-06	2.4e-05	CcSEcCtD
Cyclophosphamide—Decreased appetite—Epirubicin—hematologic cancer	2.9e-06	2.39e-05	CcSEcCtD
Cyclophosphamide—Hypotension—Doxorubicin—hematologic cancer	2.89e-06	2.38e-05	CcSEcCtD
Cyclophosphamide—Fatigue—Epirubicin—hematologic cancer	2.88e-06	2.37e-05	CcSEcCtD
Cyclophosphamide—Pain—Epirubicin—hematologic cancer	2.86e-06	2.35e-05	CcSEcCtD
Cyclophosphamide—Constipation—Epirubicin—hematologic cancer	2.86e-06	2.35e-05	CcSEcCtD
Cyclophosphamide—Urticaria—Methotrexate—hematologic cancer	2.84e-06	2.33e-05	CcSEcCtD
Cyclophosphamide—Dizziness—Prednisone—hematologic cancer	2.82e-06	2.32e-05	CcSEcCtD
Cyclophosphamide—Body temperature increased—Methotrexate—hematologic cancer	2.82e-06	2.32e-05	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.82e-06	2.32e-05	CcSEcCtD
Cyclophosphamide—Paraesthesia—Doxorubicin—hematologic cancer	2.78e-06	2.28e-05	CcSEcCtD
Cyclophosphamide—Dyspnoea—Doxorubicin—hematologic cancer	2.76e-06	2.27e-05	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Epirubicin—hematologic cancer	2.75e-06	2.26e-05	CcSEcCtD
Cyclophosphamide—Vomiting—Prednisone—hematologic cancer	2.72e-06	2.23e-05	CcSEcCtD
Cyclophosphamide—Rash—Prednisone—hematologic cancer	2.69e-06	2.22e-05	CcSEcCtD
Cyclophosphamide—Dermatitis—Prednisone—hematologic cancer	2.69e-06	2.21e-05	CcSEcCtD
Cyclophosphamide—Decreased appetite—Doxorubicin—hematologic cancer	2.69e-06	2.21e-05	CcSEcCtD
Cyclophosphamide—Headache—Prednisone—hematologic cancer	2.68e-06	2.2e-05	CcSEcCtD
Cyclophosphamide—Fatigue—Doxorubicin—hematologic cancer	2.66e-06	2.19e-05	CcSEcCtD
Cyclophosphamide—Urticaria—Epirubicin—hematologic cancer	2.65e-06	2.18e-05	CcSEcCtD
Cyclophosphamide—Constipation—Doxorubicin—hematologic cancer	2.64e-06	2.17e-05	CcSEcCtD
Cyclophosphamide—Pain—Doxorubicin—hematologic cancer	2.64e-06	2.17e-05	CcSEcCtD
Cyclophosphamide—Body temperature increased—Epirubicin—hematologic cancer	2.64e-06	2.17e-05	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Methotrexate—hematologic cancer	2.63e-06	2.16e-05	CcSEcCtD
Cyclophosphamide—Asthenia—Methotrexate—hematologic cancer	2.56e-06	2.11e-05	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Doxorubicin—hematologic cancer	2.55e-06	2.1e-05	CcSEcCtD
Cyclophosphamide—Nausea—Prednisone—hematologic cancer	2.54e-06	2.09e-05	CcSEcCtD
Cyclophosphamide—Pruritus—Methotrexate—hematologic cancer	2.53e-06	2.08e-05	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Epirubicin—hematologic cancer	2.46e-06	2.02e-05	CcSEcCtD
Cyclophosphamide—Urticaria—Doxorubicin—hematologic cancer	2.46e-06	2.02e-05	CcSEcCtD
Cyclophosphamide—Body temperature increased—Doxorubicin—hematologic cancer	2.44e-06	2.01e-05	CcSEcCtD
Cyclophosphamide—Diarrhoea—Methotrexate—hematologic cancer	2.44e-06	2.01e-05	CcSEcCtD
Cyclophosphamide—Asthenia—Epirubicin—hematologic cancer	2.4e-06	1.97e-05	CcSEcCtD
Cyclophosphamide—Pruritus—Epirubicin—hematologic cancer	2.36e-06	1.94e-05	CcSEcCtD
Cyclophosphamide—Dizziness—Methotrexate—hematologic cancer	2.36e-06	1.94e-05	CcSEcCtD
Cyclophosphamide—Diarrhoea—Epirubicin—hematologic cancer	2.29e-06	1.88e-05	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Doxorubicin—hematologic cancer	2.28e-06	1.87e-05	CcSEcCtD
Cyclophosphamide—Vomiting—Methotrexate—hematologic cancer	2.27e-06	1.87e-05	CcSEcCtD
Cyclophosphamide—Rash—Methotrexate—hematologic cancer	2.25e-06	1.85e-05	CcSEcCtD
Cyclophosphamide—Dermatitis—Methotrexate—hematologic cancer	2.25e-06	1.85e-05	CcSEcCtD
Cyclophosphamide—Headache—Methotrexate—hematologic cancer	2.24e-06	1.84e-05	CcSEcCtD
Cyclophosphamide—Asthenia—Doxorubicin—hematologic cancer	2.22e-06	1.82e-05	CcSEcCtD
Cyclophosphamide—Dizziness—Epirubicin—hematologic cancer	2.21e-06	1.82e-05	CcSEcCtD
Cyclophosphamide—Pruritus—Doxorubicin—hematologic cancer	2.19e-06	1.8e-05	CcSEcCtD
Cyclophosphamide—Vomiting—Epirubicin—hematologic cancer	2.12e-06	1.75e-05	CcSEcCtD
Cyclophosphamide—Nausea—Methotrexate—hematologic cancer	2.12e-06	1.74e-05	CcSEcCtD
Cyclophosphamide—Diarrhoea—Doxorubicin—hematologic cancer	2.11e-06	1.74e-05	CcSEcCtD
Cyclophosphamide—Rash—Epirubicin—hematologic cancer	2.11e-06	1.73e-05	CcSEcCtD
Cyclophosphamide—Dermatitis—Epirubicin—hematologic cancer	2.1e-06	1.73e-05	CcSEcCtD
Cyclophosphamide—Headache—Epirubicin—hematologic cancer	2.09e-06	1.72e-05	CcSEcCtD
Cyclophosphamide—Dizziness—Doxorubicin—hematologic cancer	2.04e-06	1.68e-05	CcSEcCtD
Cyclophosphamide—Nausea—Epirubicin—hematologic cancer	1.98e-06	1.63e-05	CcSEcCtD
Cyclophosphamide—Vomiting—Doxorubicin—hematologic cancer	1.97e-06	1.62e-05	CcSEcCtD
Cyclophosphamide—Rash—Doxorubicin—hematologic cancer	1.95e-06	1.6e-05	CcSEcCtD
Cyclophosphamide—Dermatitis—Doxorubicin—hematologic cancer	1.95e-06	1.6e-05	CcSEcCtD
Cyclophosphamide—Headache—Doxorubicin—hematologic cancer	1.94e-06	1.59e-05	CcSEcCtD
Cyclophosphamide—Nausea—Doxorubicin—hematologic cancer	1.84e-06	1.51e-05	CcSEcCtD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	1.68e-06	0.000139	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—ENO2—hematologic cancer	1.68e-06	0.000139	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—MTR—hematologic cancer	1.67e-06	0.000139	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—ABCG2—hematologic cancer	1.67e-06	0.000139	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—NUP98—hematologic cancer	1.67e-06	0.000138	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—CYCS—hematologic cancer	1.65e-06	0.000137	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—NUP98—hematologic cancer	1.65e-06	0.000137	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—HSP90AA1—hematologic cancer	1.64e-06	0.000136	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—MTHFR—hematologic cancer	1.64e-06	0.000136	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—ENO2—hematologic cancer	1.64e-06	0.000136	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—GSTT1—hematologic cancer	1.63e-06	0.000135	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—ADCY7—hematologic cancer	1.62e-06	0.000134	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—NCOA3—hematologic cancer	1.62e-06	0.000134	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	1.61e-06	0.000133	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—NUP214—hematologic cancer	1.61e-06	0.000133	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—ADCY7—hematologic cancer	1.6e-06	0.000133	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—NCOA3—hematologic cancer	1.6e-06	0.000133	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	1.6e-06	0.000133	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—FHL2—hematologic cancer	1.6e-06	0.000132	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—NUP214—hematologic cancer	1.59e-06	0.000132	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—SDC1—hematologic cancer	1.59e-06	0.000132	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—GSTT1—hematologic cancer	1.59e-06	0.000132	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—PIK3CB—hematologic cancer	1.59e-06	0.000132	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	1.58e-06	0.000131	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—ABCG2—hematologic cancer	1.57e-06	0.000131	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—MTR—hematologic cancer	1.57e-06	0.000131	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—AGRN—hematologic cancer	1.57e-06	0.00013	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—MTR—hematologic cancer	1.56e-06	0.000129	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—ABCG2—hematologic cancer	1.56e-06	0.000129	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—SDC1—hematologic cancer	1.55e-06	0.000129	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—ENO2—hematologic cancer	1.54e-06	0.000128	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	1.54e-06	0.000128	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—ENO2—hematologic cancer	1.53e-06	0.000127	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	1.52e-06	0.000126	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—CD44—hematologic cancer	1.51e-06	0.000126	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—NQO1—hematologic cancer	1.51e-06	0.000126	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—MTHFR—hematologic cancer	1.5e-06	0.000125	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	1.5e-06	0.000124	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—GSTT1—hematologic cancer	1.5e-06	0.000124	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—GSTP1—hematologic cancer	1.49e-06	0.000124	CbGpPWpGaD
Cyclophosphamide—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	1.49e-06	0.000123	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—IDH2—hematologic cancer	1.48e-06	0.000123	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—HMMR—hematologic cancer	1.48e-06	0.000123	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—GSTT1—hematologic cancer	1.48e-06	0.000123	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.48e-06	0.000123	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—SDC1—hematologic cancer	1.46e-06	0.000121	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	1.46e-06	0.000121	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—GSTP1—hematologic cancer	1.46e-06	0.000121	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—SDC1—hematologic cancer	1.45e-06	0.00012	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	1.43e-06	0.000119	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—CYCS—hematologic cancer	1.43e-06	0.000119	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—HSP90AA1—hematologic cancer	1.42e-06	0.000118	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—ABCB1—hematologic cancer	1.41e-06	0.000117	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—ARNTL—hematologic cancer	1.4e-06	0.000116	CbGpPWpGaD
Cyclophosphamide—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	1.39e-06	0.000116	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	1.39e-06	0.000115	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—ABCB1—hematologic cancer	1.38e-06	0.000115	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—PIK3CG—hematologic cancer	1.38e-06	0.000114	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—GSTM1—hematologic cancer	1.37e-06	0.000114	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—NCOR1—hematologic cancer	1.37e-06	0.000114	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—PTEN—hematologic cancer	1.37e-06	0.000114	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	1.37e-06	0.000113	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—CA9—hematologic cancer	1.36e-06	0.000113	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—ACP5—hematologic cancer	1.36e-06	0.000113	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—CD44—hematologic cancer	1.35e-06	0.000112	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—NQO1—hematologic cancer	1.35e-06	0.000112	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—GSTM1—hematologic cancer	1.34e-06	0.000111	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—NCOR1—hematologic cancer	1.34e-06	0.000111	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—NCOR2—hematologic cancer	1.34e-06	0.000111	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.32e-06	0.00011	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—CD44—hematologic cancer	1.32e-06	0.00011	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—NQO1—hematologic cancer	1.32e-06	0.00011	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—EP300—hematologic cancer	1.31e-06	0.000109	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	1.31e-06	0.000109	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.28e-06	0.000106	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—CYCS—hematologic cancer	1.28e-06	0.000106	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—CREBBP—hematologic cancer	1.28e-06	0.000106	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—IDH1—hematologic cancer	1.28e-06	0.000106	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—HSP90AA1—hematologic cancer	1.27e-06	0.000106	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—GSTP1—hematologic cancer	1.26e-06	0.000105	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—PIK3CG—hematologic cancer	1.26e-06	0.000105	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GSTO1—hematologic cancer	1.26e-06	0.000105	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—TXN—hematologic cancer	1.26e-06	0.000105	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—ABCC3—hematologic cancer	1.26e-06	0.000105	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—CYCS—hematologic cancer	1.25e-06	0.000104	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—CD44—hematologic cancer	1.24e-06	0.000103	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—NQO1—hematologic cancer	1.24e-06	0.000103	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—HSP90AA1—hematologic cancer	1.24e-06	0.000103	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—SPHK1—hematologic cancer	1.23e-06	0.000102	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—NQO1—hematologic cancer	1.23e-06	0.000102	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—CD44—hematologic cancer	1.23e-06	0.000102	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.22e-06	0.000101	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—MTHFR—hematologic cancer	1.21e-06	0.000101	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—PIK3CD—hematologic cancer	1.21e-06	0.0001	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.21e-06	0.0001	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—ABCB1—hematologic cancer	1.2e-06	9.93e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—ALB—hematologic cancer	1.19e-06	9.92e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—UGT1A1—hematologic cancer	1.19e-06	9.85e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—MTHFR—hematologic cancer	1.18e-06	9.83e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—CYCS—hematologic cancer	1.18e-06	9.77e-05	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—CREBBP—hematologic cancer	1.17e-06	9.71e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	1.17e-06	9.71e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—CYCS—hematologic cancer	1.17e-06	9.68e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—NCOR1—hematologic cancer	1.16e-06	9.64e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—GSTM1—hematologic cancer	1.16e-06	9.64e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	1.16e-06	9.62e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—SLC22A1—hematologic cancer	1.15e-06	9.58e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—CRABP1—hematologic cancer	1.15e-06	9.58e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.14e-06	9.5e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—PIK3R1—hematologic cancer	1.14e-06	9.49e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—GSTP1—hematologic cancer	1.13e-06	9.36e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—ALOX5—hematologic cancer	1.12e-06	9.33e-05	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—PIK3CD—hematologic cancer	1.11e-06	9.21e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—GSTP1—hematologic cancer	1.1e-06	9.14e-05	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—ALB—hematologic cancer	1.1e-06	9.09e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.09e-06	9.06e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—NUP98—hematologic cancer	1.09e-06	9.04e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—ABCB1—hematologic cancer	1.07e-06	8.86e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—ADCY7—hematologic cancer	1.06e-06	8.78e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—NCOA3—hematologic cancer	1.06e-06	8.78e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—PIK3CB—hematologic cancer	1.06e-06	8.76e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—NUP214—hematologic cancer	1.05e-06	8.71e-05	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—PIK3R1—hematologic cancer	1.05e-06	8.7e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.04e-06	8.66e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—GSTP1—hematologic cancer	1.04e-06	8.61e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—NCOR1—hematologic cancer	1.04e-06	8.6e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—GSTM1—hematologic cancer	1.04e-06	8.6e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—MTR—hematologic cancer	1.03e-06	8.54e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—ABCG2—hematologic cancer	1.03e-06	8.54e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—GSTP1—hematologic cancer	1.03e-06	8.54e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—MTHFR—hematologic cancer	1.03e-06	8.52e-05	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—PIK3CG—hematologic cancer	1.02e-06	8.45e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—NCOR1—hematologic cancer	1.01e-06	8.4e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—GSTM1—hematologic cancer	1.01e-06	8.4e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—ENO2—hematologic cancer	1.01e-06	8.37e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—PIK3CG—hematologic cancer	9.95e-07	8.26e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	9.95e-07	8.26e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—ABCB1—hematologic cancer	9.82e-07	8.15e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GSTT1—hematologic cancer	9.78e-07	8.12e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—ABCB1—hematologic cancer	9.73e-07	8.08e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—PIK3CA—hematologic cancer	9.67e-07	8.03e-05	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—PIK3CB—hematologic cancer	9.67e-07	8.03e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—SDC1—hematologic cancer	9.56e-07	7.94e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—NCOR1—hematologic cancer	9.53e-07	7.91e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—GSTM1—hematologic cancer	9.53e-07	7.91e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—GSTM1—hematologic cancer	9.45e-07	7.84e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—NCOR1—hematologic cancer	9.45e-07	7.84e-05	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—CREBBP—hematologic cancer	9.44e-07	7.84e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—CREBBP—hematologic cancer	9.23e-07	7.66e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—MTHFR—hematologic cancer	9.16e-07	7.6e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—PTEN—hematologic cancer	9.12e-07	7.57e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	9.04e-07	7.51e-05	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—PIK3CD—hematologic cancer	8.95e-07	7.43e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—MTHFR—hematologic cancer	8.94e-07	7.42e-05	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—ALB—hematologic cancer	8.84e-07	7.34e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—PIK3CD—hematologic cancer	8.75e-07	7.26e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—EP300—hematologic cancer	8.69e-07	7.22e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—ALB—hematologic cancer	8.64e-07	7.17e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—PIK3CG—hematologic cancer	8.62e-07	7.16e-05	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—PIK3R1—hematologic cancer	8.45e-07	7.02e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—MTHFR—hematologic cancer	8.42e-07	6.99e-05	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—PTEN—hematologic cancer	8.36e-07	6.94e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—MTHFR—hematologic cancer	8.35e-07	6.93e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—PIK3R1—hematologic cancer	8.26e-07	6.86e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—CD44—hematologic cancer	8.13e-07	6.75e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—NQO1—hematologic cancer	8.13e-07	6.75e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	8.07e-07	6.7e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—CREBBP—hematologic cancer	7.99e-07	6.63e-05	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—EP300—hematologic cancer	7.97e-07	6.62e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—AKT1—hematologic cancer	7.9e-07	6.56e-05	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—PIK3CB—hematologic cancer	7.8e-07	6.48e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PIK3CG—hematologic cancer	7.7e-07	6.39e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—CYCS—hematologic cancer	7.69e-07	6.39e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	7.64e-07	6.35e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—PIK3CB—hematologic cancer	7.63e-07	6.33e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—PIK3CD—hematologic cancer	7.58e-07	6.29e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PIK3CG—hematologic cancer	7.51e-07	6.23e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—ALB—hematologic cancer	7.48e-07	6.21e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	7.36e-07	6.11e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—PIK3R1—hematologic cancer	7.16e-07	5.94e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—CREBBP—hematologic cancer	7.13e-07	5.92e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PIK3CG—hematologic cancer	7.08e-07	5.87e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PIK3CG—hematologic cancer	7.02e-07	5.82e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—CREBBP—hematologic cancer	6.96e-07	5.78e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GSTP1—hematologic cancer	6.78e-07	5.63e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PIK3CD—hematologic cancer	6.76e-07	5.61e-05	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—PTEN—hematologic cancer	6.74e-07	5.6e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—ALB—hematologic cancer	6.68e-07	5.54e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—PIK3CB—hematologic cancer	6.61e-07	5.48e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PIK3CD—hematologic cancer	6.6e-07	5.48e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—PTEN—hematologic cancer	6.59e-07	5.47e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—CREBBP—hematologic cancer	6.56e-07	5.45e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—ALB—hematologic cancer	6.52e-07	5.41e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—CREBBP—hematologic cancer	6.51e-07	5.4e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—PIK3CA—hematologic cancer	6.43e-07	5.34e-05	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—EP300—hematologic cancer	6.43e-07	5.34e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—ABCB1—hematologic cancer	6.42e-07	5.33e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PIK3R1—hematologic cancer	6.39e-07	5.3e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—EP300—hematologic cancer	6.29e-07	5.22e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PIK3R1—hematologic cancer	6.23e-07	5.18e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—NCOR1—hematologic cancer	6.23e-07	5.17e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GSTM1—hematologic cancer	6.23e-07	5.17e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PIK3CD—hematologic cancer	6.22e-07	5.16e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PIK3CD—hematologic cancer	6.17e-07	5.12e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—ALB—hematologic cancer	6.14e-07	5.1e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—ALB—hematologic cancer	6.09e-07	5.05e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PIK3CB—hematologic cancer	5.9e-07	4.89e-05	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—PIK3CA—hematologic cancer	5.9e-07	4.89e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PIK3R1—hematologic cancer	5.88e-07	4.88e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PIK3R1—hematologic cancer	5.82e-07	4.83e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PIK3CB—hematologic cancer	5.76e-07	4.78e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—PTEN—hematologic cancer	5.71e-07	4.74e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—MTHFR—hematologic cancer	5.51e-07	4.57e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—EP300—hematologic cancer	5.44e-07	4.52e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PIK3CB—hematologic cancer	5.42e-07	4.5e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PIK3CB—hematologic cancer	5.38e-07	4.46e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—AKT1—hematologic cancer	5.25e-07	4.36e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PTEN—hematologic cancer	5.1e-07	4.23e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PTEN—hematologic cancer	4.97e-07	4.13e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—EP300—hematologic cancer	4.86e-07	4.03e-05	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—AKT1—hematologic cancer	4.82e-07	4e-05	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—PIK3CA—hematologic cancer	4.76e-07	3.95e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—EP300—hematologic cancer	4.74e-07	3.94e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PTEN—hematologic cancer	4.69e-07	3.89e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—PIK3CA—hematologic cancer	4.65e-07	3.86e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PTEN—hematologic cancer	4.65e-07	3.86e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PIK3CG—hematologic cancer	4.63e-07	3.84e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—EP300—hematologic cancer	4.47e-07	3.71e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—EP300—hematologic cancer	4.43e-07	3.68e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—CREBBP—hematologic cancer	4.29e-07	3.56e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PIK3CD—hematologic cancer	4.07e-07	3.38e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—PIK3CA—hematologic cancer	4.03e-07	3.34e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—ALB—hematologic cancer	4.02e-07	3.33e-05	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—AKT1—hematologic cancer	3.89e-07	3.23e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PIK3R1—hematologic cancer	3.84e-07	3.19e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—AKT1—hematologic cancer	3.8e-07	3.15e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PIK3CA—hematologic cancer	3.59e-07	2.98e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PIK3CB—hematologic cancer	3.55e-07	2.94e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PIK3CA—hematologic cancer	3.51e-07	2.91e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PIK3CA—hematologic cancer	3.31e-07	2.74e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—AKT1—hematologic cancer	3.29e-07	2.73e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PIK3CA—hematologic cancer	3.28e-07	2.72e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PTEN—hematologic cancer	3.06e-07	2.54e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—AKT1—hematologic cancer	2.94e-07	2.44e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—EP300—hematologic cancer	2.92e-07	2.43e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—AKT1—hematologic cancer	2.87e-07	2.38e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—AKT1—hematologic cancer	2.7e-07	2.24e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—AKT1—hematologic cancer	2.68e-07	2.22e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PIK3CA—hematologic cancer	2.16e-07	1.79e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—AKT1—hematologic cancer	1.77e-07	1.47e-05	CbGpPWpGaD
